| Sustained response of metastatic clear-cell renal-cell carcinoma to temsirolimus after sunitinib failure: A case report |
|
Yongjun Cha, Su Hyun Kim, Yoon-Su Lee, Jeong-Ok Lee, Hyun-Mi Bae, Sung Hoon Sim, Se-Hoon Lee |
|
|
| Sunitinib 치료 실패 후 temsirolimus에 반응한 신장암 1예 |
|
차용준, 김수현, 이윤수, 이정옥, 배현미, 심성훈, 이세훈 |
|
|
|
|
|
|
| Abstract |
|
Hypoxia-inducible factor-1 (HIF-1) alpha activation following dysfunction of the von Hippel–Lindau (VHL) tumor suppressor gene is one of the major oncogenic pathways in renal-cell carcinoma. Temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, downregulates mTOR-dependent HIF-1 translation and was recently shown to prolong the overall and progression-free survival compared with interferon alpha in patients with advanced renal-cell carcinoma and poor prognostic factors. Here, we report the case of a patient with metastatic clear-cell renal-cell carcinoma who showed a dramatic, sustained response to temsirolimus after progression on sunitinib therapy. This report confirms the considerable anti-tumor effect of temsirolimus in clear-cell renal-cell carcinoma patients |
| Key Words:
Renal-cell carcinoma; Temsirolimus; Sunitinib maleate |
|
PDF Links
Full text via DOI
Download Citation
